Squadron Capital Management LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2050709) · Explore on the interactive board
Squadron Capital Management LLC disclosed 34 US equity positions worth $292.1m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is RLMD at 17.4% of the reported book, followed by CCCC, COGT. The top ten holdings are 73.0% of the book, and the portfolio behaves like about 13 equal-weight positions. Versus the prior filing it opened 17 new positions, added to 9, reduced 6 and exited 13. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Squadron Capital Management LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 17 new, 9 added, 6 reduced, 13 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 17.4% | $50.9m | 7,350,000 | -13% | reduced |
| 2 | CCCC C4 THERAPEUTICS INC | Healthcare | 11.5% | $33.6m | 7,200,000 | 220% | added |
| 3 | COGT COGENT BIOSCIENCES INC | Healthcare | 11.5% | $33.5m | 865,000 | 10% | added |
| 4 | KOD KODIAK SCIENCES INC | Healthcare | 6.7% | $19.5m | 500,000 | 32% | added |
| 5 | RLAY RELAY THERAPEUTICS INC | Healthcare | 6.2% | $18.1m | 970,000 | 44% | added |
| 6 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 6.1% | $17.9m | 3,700,000 | 2% | added |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 4.0% | $11.8m | 290,000 | -17% | reduced |
| 8 | MAZE MAZE THERAPEUTICS INC | Healthcare | 3.4% | $10.0m | 335,000 | 30% | added |
| 9 | IVA INVENTIVA SA | 3.2% | $9.2m | 2,435,000 | 355% | added | |
| 10 | ANL ADLAI NORTYE LTD | 3.0% | $8.8m | 764,876 | -40% | reduced | |
| 11 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 2.8% | $8.1m | 160,000 | – | new |
| 12 | PALI PALISADE BIO INC | Healthcare | 2.1% | $6.3m | 3,000,000 | 0% | held |
| 13 | IKT INHIBIKASE THERAPEUTICS INC | 2.1% | $6.1m | 3,000,000 | -14% | reduced | |
| 14 | ADAG ADAGENE INC | 1.8% | $5.2m | 1,250,000 | – | new | |
| 15 | FBRX FORTE BIOSCIENCES INC | 1.6% | $4.8m | 225,000 | – | new | |
| 16 | INFLARX NV | 1.5% | $4.5m | 2,000,000 | – | new | |
| 17 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 1.5% | $4.4m | 160,000 | – | new |
| 18 | PROMIS NEUROSCIENCES INC | 1.5% | $4.3m | 324,977 | 0% | held | |
| 19 | CTNM CONTINEUM THERAPEUTICS INC | 1.5% | $4.3m | 260,000 | – | new | |
| 20 | CMPS COMPASS PATHWAYS PLC | Healthcare | 1.5% | $4.2m | 300,000 | – | new |
| 21 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.4% | $4.0m | 85,000 | – | new |
| 22 | SOL-GEL TECHNOLOGIES LTD | 1.3% | $3.9m | 52,000 | 68% | added | |
| 23 | BIOA BIOAGE LABS INC | 1.3% | $3.8m | 155,000 | – | new | |
| 24 | SCYX SCYNEXIS INC | 1.1% | $3.1m | 756,884 | – | new | |
| 25 | PROQR THRAPEUTICS N V | 1.0% | $2.8m | 1,511,496 | – | new | |
| 26 | RZLT REZOLUTE INC | 0.7% | $2.1m | 403,410 | – | new | |
| 27 | LPCN LIPOCINE INC NEW | 0.7% | $2.1m | 810,000 | 80% | added | |
| 28 | CUE CUE BIOPHARMA INC | 0.5% | $1.6m | 50,000 | – | new | |
| 29 | CALC CALCIMEDICA INC | 0.4% | $1.3m | 1,244,864 | – | new | |
| 30 | QUINCE THERAPEUTICS INC | 0.3% | $734.4k | 40,375 | – | new | |
| 31 | KTTA PASITHEA THERAPEUTICS CORP | 0.2% | $515.4k | 1,000,000 | -52% | reduced | |
| 32 | INM INMED PHARMACEUTICALS INC | 0.2% | $503.8k | 325,000 | – | new | |
| 33 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 0.1% | $170.0k | 100,000 | – | new |
| 34 | NXTC NEXTCURE INC | 0.0% | $103.1k | 64,464 | -76% | reduced |
What did Squadron Capital Management LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 4XC1 KALVISTA PHARMACEUTICALS INC | 28.8% | $19.8m |
| ABVX ABIVAX SA | 21.0% | $14.5m |
| NKTR NEKTAR THERAPEUTICS | 13.0% | $9.0m |
| SCYX SCYNEXIS INC | 10.1% | $7.0m |
| EPRX EUPRAXIA PHARMACEUTICALS INC | 7.1% | $4.9m |
| GHRS GH RESEARCH PLC | 6.6% | $4.6m |
| ALXO ALX ONCOLOGY HLDGS INC | 4.2% | $2.9m |
| CNTX CONTEXT THERAPEUTICS INC | 4.2% | $2.9m |
| TRAW TRAWS PHARMA INC | 1.4% | $936.4k |
| TXMD THERAPEUTICSMD INC | 1.2% | $849.2k |
| SPRB SPRUCE BIOSCIENCES INC | 1.2% | $797.3k |
| HOWL WEREWOLF THERAPEUTICS INC | 0.7% | $469.2k |
| NEUP NEUPHORIA THERAPEUTICS INC | 0.5% | $312.3k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 76.2% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Squadron Capital Management LLC's portfolio?
Across every quarter Squadron Capital Management LLC has filed, its median largest position is 20.5% of the book and its median top-ten weight is 73.1%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 12.0 completed holding spells, the median lasted 1.0 quarters; 34.0 positions are still open and their final length is unknown.